C4 Therapeutics (CCCC) Liabilities and Shareholders Equity (2019 - 2026)

C4 Therapeutics' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $328.9 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 2.92% year-over-year to $328.9 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 12.36% decrease from a year earlier, with the FY2025 full-year figure at $359.1 million, up 2.71% from the prior year.
• Liabilities and Shareholders Equity eased to $328.9 million in Q1 2026 per CCCC's latest filing, from $359.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $515.5 million in Q1 2022 and bottomed at $265.5 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $376.1 million (2024), against an average of $379.7 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 37.83% in 2022 and fell 29.4% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $430.8 million in 2022, then retreated by 12.62% to $376.5 million in 2023, then dropped by 7.13% to $349.6 million in 2024, then increased by 2.71% to $359.1 million in 2025, then slipped by 8.41% to $328.9 million in 2026.
• Per Business Quant, the three latest CCCC Liabilities and Shareholders Equity figures stand at $328.9 million (Q1 2026), $359.1 million (Q4 2025), and $265.5 million (Q3 2025).